Video Library

BioMarin is committed to supporting the healthcare community with a range of resources for healthcare professionals. This resource library contains links to videos, websites and other information on our products and diseases.

Video Library for Our Products

BRINEURA® (cerliponase alfa)

KUVAN® (sapropterin dihydrochloride)

NAGLAZYME® (galsulfase (rch))

VIMIZIM® (elosulfase alfa (rch))

VOXZOGO® (vosoritide)

Video Library for Our Therapy Areas

Achondroplasia

Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease

Maroteaux-Lamy syndrome (MPS VI)

Morquio A (MPS IVA)

Phenylketonuria (PKU)

Products available in Australia

BRINEURA® (cerliponase alfa)

BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

KUVAN® (sapropterin dihydrochloride)

KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) in sapropterin-responsive adult and paediatric patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.

NAGLAZYME® (galsulfase (rch))

NAGLAZYME® is indicated as long term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, Nacetylgalactosamine 4- sulfatase deficiency, Maroteaux-Lamy syndrome).

VIMIZIM® (elosulfase alfa (rch))

VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis type IVA, morquio A syndrome).

VOXZOGO® (vosoritide)

VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.